Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06470451 · ClinicalTrials.gov registry record · Phase 3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

A Phase 3 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by Soligenix.

Recruiting
Registry status
Phase 3
Development phase
80
Enrollment target
17
Study locations

NCT06470451 is a Phase 3 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides that is actively recruiting participants, run by Soligenix. The registered enrollment target is 80 participants, above the 64-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (25% higher). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06470451, a Phase 3 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, is actively recruiting participants, sponsored by Soligenix.

RECRUITING
Registry status
Phase 3
Development phase
80 participants
Enrollment target
17
Study locations

Study Summary

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

Conditions Studied

Cutaneous T Cell Lymphoma Mycosis Fungoides CTCL CTCL/ Mycosis Fungoides

Interventions

  • DRUG Placebo
  • DRUG Hypericin

Study Locations (17)

Pennsylvania

  • Penn State Health Hershey Medical Center - Hershey
  • Hospital of the University of Pennsylvania - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Arizona

  • Medical Dermatology Specialists - Phoenix
  • Mayo Clinic - Scottsdale

New York

  • Rochester Skin Lymphoma Medical Group - Fairport
  • Columbia University Medical Center - New York

Texas

  • MD Anderson - Houston
  • Austin Institute for Clinical Research - Pflugerville

California

  • Therapeutics Clinical Research - San Diego

Florida

  • University of South Florida - Tampa

Illinois

  • Northwestern University - Chicago

Indiana

  • Dawes Fretzin Dermatology Group - Indianapolis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-01-07
Est. Completion 2026-10
Phase Phase 3

Sponsor

Soligenix

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06470451

The ClinicalTrials.gov registry entry for NCT06470451 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (25% higher). The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06470451 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Pennsylvania, Arizona, New York.

Frequently Asked Questions

What is clinical trial NCT06470451 about?

NCT06470451 is a clinical study titled "Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL". To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

What is the current status of trial NCT06470451?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2025-01-07. Estimated completion is 2026-10.

What conditions does trial NCT06470451 study?

This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides, CTCL, CTCL/ Mycosis Fungoides.

What interventions are being tested in trial NCT06470451?

The interventions under investigation include: Placebo (DRUG), Hypericin (DRUG).

Who is sponsoring clinical trial NCT06470451?

This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06470451 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cutaneous T Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cutaneous T Cell Lymphoma

All registered trials for this condition

Mycosis Fungoides

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.